염산펙소페나딘 120밀리그람 정제의 생물학적동등성시험

조혜영,강현아,김세미,이용복,Cho, Hea-Young,Kang, Hyun-Ah,Kim, Se-Mi,Lee, Yong-Bok 대한약학회 2008 약학회지 Vol.52 No.3

Fexofenadine, ($\pm$)-4-1-hydroxy-4-{4-(hydroxydiphenylmethyl)-1-piperidinyl}-butyl-a,a-dimethyl benzeneacetic acid, is a selective histamine $H_1$ receptor antagonist, and is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria as a first-line therapeutic agent. The purpose of the present study was to evaluate the bioequivalence of two fexofenadine hydrochloride tablets, $Allegra^{(R)}$ (Handok Pharmaceuticals Co., Ltd.) and Alecort (Samchundang Pharmaceutical Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of fexofenadine from the two fexofenadine hydrochloride formulations in vitro was tested using KP VIII Apparatus II method with various dissolution media. Twenty six healthy male subjects, 25.62$\pm$3.35 years in age and 70.05$\pm$11.71 kg in body weight, were divided into two groups and a randomized 2$\times$2 cross-over study was employed. After a single tablet containing 120 mg as fexofenadine hydrochloride was orally administered, blood samples were taken at predetermined time intervals and the concentrations of fexofenadine in serum were determined using HPLC with fluorescence detector. The dissolution profiles of two formulations were similar in all tested dissolution media. The harmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated, and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Allegra^{(R)}$, were -1.37, 5.22 and 16.50% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., log 0.83$\sim$log 1.08 and log 0.81$\sim$log 1.03 for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Alecort tablet was bioequivalent to $Allegra^{(R)}$ tablet.

응급구조사의 극복력 측정도구 개발

조혜영,박성희,Cho, Hye-Young,Park, Sung-Hee 한국응급구조학회 2018 한국응급구조학회지 Vol.22 No.2

Purpose: This study aimed to develop a resilience measurement scale and verify its validity and reliability. Methods: This was a methodological study. The preliminary items of the scale were derived from literature reviews and in-depth interviews. The data were collected from October 30, 2017 to January 20, 2018, and paramedics working in hospitals or fire departments were selected using convenience sampling. A self-reported questionnaire was completed by 213 paramedics in Korea. Results: Through content validity, item analysis and exploratory factor analysis, a total of 6 factors and 26 items were extracted, and the total variance was 67.12%. Factor 1 was "self-efficacy" (11 items), factor 2 was "internal control" (5 items), factor 3 was "empowerment" (2 items), factor 4 was "interpersonal capability", (3 items), factor 5 was "social support" (2 items), and factor 6 was "adaptation and coping" (3 items). Conclusion: This is the first scale developed in Korea to measure the resilience of paramedics. In future, this scale of this study will contribute to developing a resilience improvement program based on understanding the resilience level of paramedics.

밤벡$^{(R)}$ 정 10밀리그람(염산밤부테롤 10밀리그람)에 대한 밤부콜 정 10밀리그람의 생물학적동등성

조혜영,최지훈,류희두,이용복,Cho, Hea-Young,Choi, Ji-Hoon,Yoo, Hee-Doo,Lee, Yong-Bok 한국임상약학회 2010 한국임상약학회지 Vol.20 No.3

Bambuterol hydrochloride, dimethylcarbamic acid 5-[2-(1,1-dimethylethyl)amino-1-hydroxyethyl]-1,3-phenylene ester hydrochloride, is the prodrug of active ${\beta}_2$-adrenergic metabolite terbutaline. The purpose of the present study was to evaluate the bioequivalence of two bambuterol hydrochloride tablets, $Bambec^{(R)}$ tablet 10 mg (Yuhan Co., Ltd.) and Bambucol tablet 10 mg (Sam Chun Dang Pharm. Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). In vitro release of bambuterol from two bambuterol hydrochloride formulations was tested using KP VIII Apparatus II method with various dissolution media. Twenty eight healthy male Korean volunteers, $23.86{\pm}1.65$ years in age and $68.98{\pm}9.58$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After two tablets containing 10 mg as bambuterol hydrochloride were orally administered, blood samples were taken at predetermined time intervals, and the concentrations of bambuterol in serum were determined using column switching HPLC with UV detector. The dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated, and ANOVA test with K-BE Test 2002 was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Bambec^{(R)}$, were -8.10%, -3.82% and 12.65% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (i.e., log 0.8093~log 1.0302 and log 0.8564~log 1.1280 for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Bambucol tablet 10 mg was bioequivalent to $Bambec^{(R)}$ tablet 10 mg.

테놀민 정에 대한 삼천당아테놀올 정의 생물학적동등성

조혜영,강현아,이석,백승희,이용복,Cho, Hea-Young,Kang, Hyun-Ah,Lee, Suk,Baek, Seung-Hee,Lee, Yong-Bok 대한약학회 2003 약학회지 Vol.47 No.5

Atenolol is a water soluble, ${\beta}_1$ selective adrenoceptor antagonist used in the treatment of angina and hypertension. It is primarily eliminated renally with minimal hepatic metabolism. The purpose of the present study was to evaluate the bioequivalence of Samchundang Atenolol (Samchundang Pharmaceutical Co., Korea.) to Tenolmin(Hyundai Pharmaceutical Ind. Co., Korea). The atenolol release from the two atenolol tablets in vitro was tested using KP VII Apparatus II method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty four normal male volunteers, 22.83$\pm$1.99 years in age and 65.82$\pm$7.15 kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After one tablet containing 50 mg of atenolol was orally administered, blood was taken at predetermined time intervals and the concentrations of atenolol in serum were determined using HPLC method with fluorescence detector. The dissolution profiles of two atenolol tablets were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_{t}$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_{t}$ and $C_{max}$ and untransformed $T_{max}$. The results showed that the differences in $AUC_{t}$, $C_{max}$ and $T_{max}$ between two tablets based on the Tenolmin were 3.74%, 4.38% and 17.77%, respectively. There were no sequence effects between two tablets in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(0.98)∼log(1.l1) and log(0.95)∼log(1.l5) for $AUC_{t}$ and $C_{max}$ respectively), indicating that Samchundang Atenolol tablet is bioequivalent to Tenolmin tablet.

니세털 정(아세틸-엘-카르니틴 500 mg)에 대한 엘카틴 정의 생물학적 동등성

조혜영,윤지훈,오인준,문재동,이용복,Cho, Hea-Young,Yun, Ji-Hun,Oh, Injoon,Moon, Jai-Dong,Lee, Yong-Bok 한국임상약학회 2001 한국임상약학회지 Vol.11 No.2

Acetyl-L-carnitine (ALC), an endogenous component of the L-carnitine family, is a naturally existing molecule synthesized from L-carnitine (LC) by carnitine acetyl transferase. ALC has been shown to improve the cognitive performance of patients suffering from dementia of the Alzheimer's type and proposed for treating Alzheimer's disease in pharmacological doses. The purpose of the present study was to evaluate the bioefuivalence of two ALC tablets, $Nicetile^{TM} (Dong-A Pharmaceutical Co.) and $L-Cartin^{TM}$ (Kuhn Il Pharmaceutical Co.), according to the guidelines of Korea Food and Drug Administration (KFDA). The ALC release from the two ALC tablets in vitro was tested using KP VII Apparatus II method in various dissolution media (pH 1.2, 6.0 and 6.8). Twenty six normal male volunteers, $24.46\pm3.67$ years in age and $64.45\pm5.54$ kg in body weight, were divided into two groups and a randomized $2\times2$cross-over study was employed. After one tablet containing 500 mg of ALC was orally administered, blood was taken at predetermined time intervals and the concentrations of ALC in serum were determined using HPLC with fluorescence detector. Because of the presence of endogenous ALC, the calibration was performed using dialyzed serum. The dissolution profiles of the two ALC tablets were similar in all the dissolution media. The pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA was utilized for the statistical analysis of the parameters. The results showed that the differences in $AUC_t,\;C_{max}\;and\;T_{max}$ between two tablets were $0.35\%,\;0.93\%\;and\;2.34\%$ respectively, when calculated against the $Nicetile^{TM} tablet. The powers $(1-\beta)\;for\;AUC_t$ , and Cmax were $98.72\%\;and\;85.48\%$, respectively. Minimum detectable differences $(\Delta)\;at\;\alpha=0.05\;and\;1-\beta=0.8$ were less than $20\%,\;(e.g.,\;13.21\%\;and\;18.42\%\;for\;AUC_t,\;and\;C_{max}$ respectively). The $90\%$ confidence intervals were within $\pm20\%\;(e.g.,\;-7.38\sim8.09\;and\;-9.86\sim11.72\;for\;AUC_t,\;and\;C_{max}$, respectively). These two parameters met the criteria of KFDA for bioequivalence, indicating that $L-Cartin^{TM}$ tablet is bioequivalent to $Nicetile^{TM} tablet.

PVFS를 위한 I/O Tracer 설계 및 구현

조혜영 ( Hyeyoung Cho ),차광호 ( Kwangho Cha ),김성호 ( Sungho Kim ),이상동 ( Sangdong Lee ) 한국정보처리학회 2008 한국정보처리학회 학술대회논문집 Vol.15 No.2

사용자 프로그램의 I/O 패턴을 분석하거나 파일 시스템의 워크로드를 보다 정확하게 분석하기 위해서 실제 가동중인 파일 시스템의 동적 I/O 로그를 확보하기 위한 연구들이 많이 진행되어 왔다. 그러나 대량의 I/O 트렌젝션(transcation)이 처리되는 파일 시스템에서 동적 I/O 로그를 확보하는 일은 시스템의 부하와 막대한 데이터량 때문에 한계가 많다. 특히 다수의 이용자가 사용하는 대용량 분산/병렬 파일 시스템에서의 I/O Tracing은 로컬 파일 시스템에서 I/O Tracing에 비해 더욱 복잡하고 오버헤드가 크다. 본 논문에서는 기존의 파일 시스템 로깅 방법들을 알아보고, 클러스터 시스템에서 널리 이용되고 있는 분산 파일 시스템인 PVFS(Parallel Virtual File System)에서 동적 I/O 연산들의 로그를 생성할 수 있는 로깅 시스템을 제안하고 설계하였다.

ASIC 프로세서를 이용한 가속 기술에 관한 연구

조혜영 ( Hyeyoung Cho ),김성호 ( Sungho Kim ),이식 ( Sik Lee ) 한국정보처리학회 2009 한국정보처리학회 학술대회논문집 Vol.16 No.2

과학용 어플리케이션을 주로 사용하는 고성능 컴퓨팅 시장에서 연산 요구량이 증가하면서 연산 가속 기술에 대한 관심이 높아지고 있다. 컴퓨터 연산 가속의 대안으로 재설정가능반도체(FPGA)나 주문형 반도체(ASIC) 등의 전용 칩을 사용하거나 Cell 프로세서와 같이 비디오 게임용으로 개발된 게임 프로세서(Game Processor)를 과학 어플리케이션에 이용하려는 노력이 대두되고 있다. 이에 본 논문에서는 ASIC 프로세서를 이용한 대표적인 가속 프로세서인 Clearspeed Advanced e620을 대상으로 성능을 분석하고 그 타당성을 검토하였다.

1990년대 중국 문단 맥락 일별

조혜영(Cho Haeyoung) 중국문화연구학회 2012 중국문화연구 Vol.0 No.21

하멜 클러스터 시스템의 파일 시스템 워크로드 분석

조혜영 ( Hyeyoung Cho ),차광호 ( Kwangho Cha ),김성호 ( Sungho Kim ) 한국정보처리학회 2006 한국정보처리학회 학술대회논문집 Vol.13 No.2

클러스터 시스템의 응용 분야가 다양화되고 복잡해짐에 따라, 대규모 클러스터 시스템을 보다 효율적으로 사용하기 위해서 실제 사용자의 이용 패턴을 예측할 수 있는 워크로드 분석의 필요성이 높아지고 있다. 이에 본 논문에서는 256노드 규모의 현재 가동중인 클러스터 시스템에서 파일 시스템에 대한 워크로드를 분석하였다.

경,중증 파킨슨병 환자의 심상훈련이 균형과 보행능력 및 인지기능에 미치는 영향

조혜영(Hey Young Cho),김대훈(Dae Hun Kim),김용성(Yong Seong Kim) 한국사회체육학회 2013 한국사회체육학회지 Vol.0 No.54

The purpose of this study was to investigate the effectiveness of imagery training on balance, gait ability and cognition function in patients with Parkinson`s disease(PD). The subjects of this study were 17 patients with PD. Participants were randomly assigned to imagery training group(n=9) and a control group(n=8). Imagery training was executed three times in hospital and two times of at home a week for 10 weeks. All date were analyzed by two way repeated ANOVA and post hoc was paired t-test and independent t-test of SPSS/PC ver 12.0. The 10 weeks of imagery training were significantly effective in balance(functional reach test, one leg standing, time up & go, tendom walking), gait ability(10m walking) but no significantly on cognitive function. These results suggest that imagery training group were more significantly increased on balance and gait ability than control group. In conclusion, the imagery training in patients with PD may be effective for improvement balance and gait ability.